Relationship Between Insulin-Like Growth Factor Binding Protein-2 and Left Ventricular Stroke Volume in Patients With Aortic Stenosis

Canadian Journal of Cardiology

Volumn 31, Issue 12, 2015, Pages 1447-1454

  Carter, Sophie ^a,b   Capoulade, Romain ^a,b   Arsenault, Marie ^a,b   Bédard, Élisabeth ^a,b   Dumesnil, Jean G ^a   Mathieu, Patrick ^a,b   Pibarot, Philippe ^a,b   Picard, Frédéric ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN BINDING PROTEIN 2;

ADULT; AGE; AGED; AORTA STENOSIS; AORTA VALVE; AORTIC VALVE AREA; ARTICLE; BODY MASS; BODY SURFACE; CARDIOMETABOLIC RISK; CARDIOVASCULAR PARAMETERS; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; DYSLIPIDEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE; HEART STROKE VOLUME; HOMEOSTASIS; HOMEOSTATIC ASSESSMENT MODEL INDEX; HUMAN; HYPERTENSION; LEFT VENTRICULAR END DIASTOLIC DIAMETER; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; STROKE VOLUME INDEX; ABDOMINAL OBESITY; AORTA VALVE STENOSIS; BLOOD; COHORT ANALYSIS; MIDDLE AGED; PHYSIOLOGY; STATISTICS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; COHORT STUDIES; ECHOCARDIOGRAPHY, DOPPLER; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; STATISTICS AS TOPIC; STROKE VOLUME;

EID: 84938222934     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.04.024     Document Type: Article

References (36)

1. Nishimura R.A., Otto C.M., Bonow R.O., et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (erratum in: 2014;63:2489). J Am Coll Cardiol 2014, 63:2438-2488.
2. Vahanian A., Iung B. The new ESC/EACTS guidelines on the management of valvular heart disease. Arch Cardiovasc Dis 2012, 105:465-467.
3. Pibarot P., Dumesnil J.G. Improving assessment of aortic stenosis. J Am Coll Cardiol 2012, 60:169-180.
4. Hachicha Z., Dumesnil J.G., Bogaty P., Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. Circulation 2007, 115:2856-2864.
5. Dumesnil J.G., Pibarot P. Low-flow, low-gradient severe aortic stenosis in patients with normal ejection fraction. Curr Opin Cardiol 2013, 28:524-530.
6. Page A., Dumesnil J.G., Clavel M.A., et al. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin). J Am Coll Cardiol 2010, 55:1867-1874.
7. Capoulade R., Larose É., Mathieu P., et al. Visceral adiposity and left ventricular mass and function in patients with aortic stenosis: the PROGRESSA study. Can J Cardiol 2014, 30:1080-1087.
8. Firth S.M., Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002, 23:824-854.
9. Azar W.J., Zivkovic S., Werther G.A., Russo V.C. IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells. Oncogene 2014, 33:578-588.
10. Wheatcroft S.B., Kearney M.T., Shah A.M., et al. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes 2007, 56:285-294.
11. Nam S.Y., Lee E.J., Kim K.R., et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord 1997, 21:355-359.
12. Martin R.M., Holly J.M., Davey Smith G., Gunnell D. Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr Cohort. J Clin Endocrinol Metab 2006, 91:3287-3295.
13. Carter S., Li Z., Lemieux I., et al. Circulating IGFBP-2 levels are incrementally linked to correlates of the metabolic syndrome and independently associated with VLDL triglycerides. Atherosclerosis 2014, 237:645-651.
14. Heald A.H., Kaushal K., Siddals K.W., et al. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes 2006, 114:371-376.
15. Devine B.J. Gentamicin therapy. Drug Intell Clin Pharm 1974, 8:650-655.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
17. Matthews D.R., Hosker J.P., Rudenski A.S., et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
18. Cramariuc D., Cioffi G., Rieck A.E., et al. Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy. JACC Cardiovasc Imaging 2009, 2:390-399.
19. de Simone G., Devereux R.B., Daniels S.R., et al. Stroke volume and cardiac output in normotensive children and adults. Assessment of relations with body size and impact of overweight. Circulation 1997, 95:1837-1843.
20. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000, 343:611-617.
21. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005, 18:1440-1463.
22. Clavel M.A., Dumesnil J.G., Capoulade R., et al. Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. J Am Coll Cardiol 2012, 60:1259-1267.
23. Lancellotti P., Magne J., Donal E., et al. Clinical outcome in asymptomatic severe aortic stenosis: insights from the new proposed aortic stenosis grading classification. J Am Coll Cardiol 2012, 59:235-243.
24. Eleid M.F., Sorajja P., Michelena H.I., et al. Flow-gradient patterns in severe aortic stenosis with preserved ejection fraction: clinical characteristics and predictors of survival. Circulation 2013, 128:1781-1789.
25. Herrmann H.C., Pibarot P., Hueter I., et al. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. Circulation 2013, 127:2316-2326.
26. Le Ven F., Freeman M., Webb J., et al. Impact of low flow on the outcome of high-risk patients undergoing transcatheter aortic valve replacement. J Am Coll Cardiol 2013, 62:782-788.
27. Kanashiro-Takeuchi R.M., Tziomalos K., Takeuchi L.M., et al. Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. Proc Natl Acad Sci U S A 2010, 107:2604-2609.
28. Touvron M., Escoubet B., Mericskay M., et al. Locally expressed IGF1 propeptide improves mouse heart function in induced dilated cardiomyopathy by blocking myocardial fibrosis and SRF-dependent CTGF induction. Dis Model Mech 2012, 5:481-491.
29. Perks C.M., Vernon E.G., Rosendahl A.H., Tonge D., Holly J.M. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 2007, 26:5966-5972.
30. Shai S.Y., Harpf A.E., Babbitt C.J., et al. Cardiac myocyte-specific excision of the beta1 integrin gene results in myocardial fibrosis and cardiac failure. Circ Res 2002, 90:458-464.
31. Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004, 432:466-472.
32. DiMichele L.A., Doherty J.T., Rojas M., et al. Myocyte-restricted focal adhesion kinase deletion attenuates pressure overload-induced hypertrophy. Circ Res 2006, 99:636-645.
33. Li Z., Picard F. Modulation of IGFBP2 mRNA expression in white adipose tissue upon aging and obesity. Horm Metab Res 2010, 42:787-791.
34. Lopez-Otero D., Trillo-Nouche R., Gude F., et al. Pro B-type natriuretic peptide plasma value: a new criterion for the prediction of short- and long-term outcomes after transcatheter aortic valve implantation. Int J Cardiol 2013, 168:1264-1268.
35. Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005, 11(5 Suppl):S81-S83.
36. Capoulade R., Clavel M.A., Dumesnil J.G., et al. Insulin resistance and LVH progression in patients with calcific aortic stenosis: a substudy of the ASTRONOMER trial. JACC Cardiovasc Imaging 2013, 6:165-174.